Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1990-6-1
|
| pubmed:abstractText |
Seventy-four consecutive patients with high-risk acute lymphoblastic leukemia (ALL) were given cyclophosphamide (CY; 50 mg/kg on each of 4 days) plus total body irradiation (TBI; 300 rad on each of 4 days) followed by a human leukocyte antigen (HLA)-identical allogeneic bone marrow transplant (BMT). Eighteen patients in first complete remission (CR1), 36 in CR2, 16 in CR3, and four in CR4 were transplanted. Patients in CR1 were transplanted 1 to 8 months (median, 3 months) after attaining CR. All 18 patients in CR1 had one or more poor risk factors: age more than 18 (N = 17), initial leukocyte count greater than or equal to 20,000 (N = 11), Ph 1 chromosome (N = 2), delay in attaining CR more than 6 weeks (N = 8), or extramedullary disease (N = 1). Of those transplanted in CR2, 72% had relapsed on therapy. The 5-year event-free survival (EFS) rates for patients transplanted in CR1, CR2, and CR3 are 42%, 43%, and 25%, respectively, at median follow-up times of 57, 54, and 72 months, respectively. Children aged less than 18 years transplanted in CR2 have a 5-year EFS rate of 54%. All CR4 patients died early after transplant. The actuarial probability of relapse is 20%, 26%, and 48% for those transplanted in CR1, CR2, and CR3, respectively. Although there was substantial transplant-associated mortality, it decreased over the decade of the study (P = .01). This study indicates that BMT offers an attractive alternative to postremission chemotherapy in patients in CR1 with poor prognostic factors and in patients in second remission.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
820-30
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2332770-Adolescent,
pubmed-meshheading:2332770-Adult,
pubmed-meshheading:2332770-Age Factors,
pubmed-meshheading:2332770-Bone Marrow Transplantation,
pubmed-meshheading:2332770-Chi-Square Distribution,
pubmed-meshheading:2332770-Child,
pubmed-meshheading:2332770-Child, Preschool,
pubmed-meshheading:2332770-Combined Modality Therapy,
pubmed-meshheading:2332770-Female,
pubmed-meshheading:2332770-Humans,
pubmed-meshheading:2332770-Leukocyte Count,
pubmed-meshheading:2332770-Male,
pubmed-meshheading:2332770-Multivariate Analysis,
pubmed-meshheading:2332770-Philadelphia Chromosome,
pubmed-meshheading:2332770-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:2332770-Prognosis,
pubmed-meshheading:2332770-Proportional Hazards Models,
pubmed-meshheading:2332770-Recurrence,
pubmed-meshheading:2332770-Remission Induction,
pubmed-meshheading:2332770-Risk Factors,
pubmed-meshheading:2332770-Survival Rate
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia.
|
| pubmed:affiliation |
Bone Marrow Transplantation Program, Johns Hopkins Oncology Center, Baltimore, MD 21205.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|